Twotypes of recombinant human granulocyte colony-stimulating factor (rhG-CSF) are available, and equally used for mitigation of neutropenia. One is a glycosylated natural product from mammaliancells, and the other a non-glycosylated form from Escherichia coli. Thoughonly minimal adverse effects have been reported for both, we treated two patients with rhG-CSFinduced systemic eruption. Based on these patients, the following should be noted: 1) drug eruption may occur in both types ofrhG-CSF without detectable antibodies, 2) intradermal test is useful for determination of the causal drug, and 3) if one rhG-CSF product causes eruption, the alternative one maypossibly be safe and effective. (Internal Medicine 33: 641-643, 1994) 
Introduction
Recently, a large scale of production of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was established by expression in bacterial or mammalian cells (1 , 2) . The former product of rhG-CSF is deglycosylated (filgrastim), and the latter is the glycosylated natural type (lenograstim). Since the effect of both rhG-CSF products is considered identical (3), both are usually used for mitigation of neutropenia due to cancer chemotherapy (1 , 2, 4-6) . rhG-CSF in general has been associated with only minimal subjective discomfort, essentially limited to bone pain (1, 2, 4, 5) . Wetreated two cases of rhG-CSF-induced severe eruption; here we describe these patients and discuss the possible mechanism.
Case Report
Casel
A 37-year-old patient with lung cancer (stage IV) was admitted to our hospital. He had a history of cured seminoma of testis at age of 26. His mother, an uncle, and an aunt died from cancer. The diagnosis of lung cancer with multiple lung metastasis was made and a combined chemotherapy (etoposide, mitomycin-C, vindesine and cisplatin) was started on July 23, 1993. During the second cycle of the chemotherapy, he developed systemic eruption on the third day (September 10) of filgrastim administration (subcutaneously, 75\xg once a day; sameas the first cycle) for the neutropenia. The causal drug was considered to be filgrastim by the result of intradermal tests (Table 1 ). Since lenograstim was negative for intradermal test, we used lenograstim in place of filgrastim. His eruption disappeared promptly, and the same beneficial effect of rhG-CSF on his neutropenia was observed.
Case2
A 71-year-old patient with lung cancer (stage Illb) was treated with a combinedchemotherapy(the same regimen of case 1 ). After 9 days administration of lenograstim (subcutaneously, lOOjag once a day) for the chemotherapy-induced neutropenia, recovery of the number of neutrophils was observed. However, since the number of peripheral blood neutrophils was again decreased, lenograstim was re-administered in the same way. He developed severe systemic eruption ( Fig. 1 ) on July 27, 1993, the sixth day of re-administration. Intradermal tests of both rhG-CSF (lenograstim and filgrastim) were positive, although the wheal of lenograstim was much bigger than that of filgrastim. rhG-CSF was then discontinued, as the number of neutrophils had already recovered. The eruption disappeared quickly.
In both patients, anti-G-CSF antibodies were not detected and lymphocyte stimulation tests (LST) were also negative (Table 1 ). In the first patient, total serum IgE was transiently increased 4 days after his eruption appeared. ) in Japan, adverse effects were reported in 8.9% and 4.5%, respectively. Most of them were fever and bone-related pain. Skin disorders have been documented (5, 6) , but most were minor disorders, although details were not available. Systemic eruption observed in the present patients seemed to be very rare. Since intradermal test for rhG-CSFbut not for vehicle was positive in the two patients, the eruption was considered to be due to rhG-CSF. The mechanism of the eruption is unknown, but at the least type I allergic reaction maybe involved because intradermal reaction occurred within less than 15 minutes and the serum IgE level transiently increased when the eruption appeared (Case 1). Like usual drug-induced eruptions, the eruption was developed following latent time, which would be needed to give sensitization. It is interesting that intradermal reaction was strongly positive for one rhG-CSFproduct which had been used, but weakly positive or negative for the alternative one. Such a difference indicates that the small structural difference between them, a minute contamination of protein(s) , from E. coli or Chinese hamster ovary cells, would be responsible. If we can not use one product ofrhG-CSFdue to adverse effects, the other product may possibly be applicable under mandatory careful observation/as demonstrated in case 1. This notion could be supported by the fact that no antibodies to G-CSF were detectable.
Recently, Gribben et al (7) reported the development of antibodies to rhGM-CSF (granulocyte-macrophage colonystimulating factor). They noted that the clinical effect of antibody formation might not be obvious, but the antibody seemed to accelerate plasma clearance of rhGM-CSF in somecases. Antibody has also been reported in the case of recombinant human growth hormone derived from E. coli (8). These antibodies react with sites on the protein backbone which are normally protected by glycosylation but which are exposed in the non-glycosylated form. No antibody against G-CSFhas been reported even in the non-glycosylated form. Antibodies of IgG, A, and Mclass were not detected, but specific IgE antibody may be involved in the pathogenesis of the eruption.
